More recently, literature has emerged that offers multiple observations on the role of interferons (IFNs), a type of cytokines important for fighting viral infections and regulating the immune system, in the pathogenesis of SLE.7 Following two phase III trials, anifrolumab, a monoclonal antibody which binds to type I IFN receptor subunit 1 (IFNAR1), inhibiting the activity of type I IFNs, was approved for active SLE.8 This evidence concerns the gene IFNAR1 and systemic lupus erythematosus.